Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13516238 | 0.78 | PPARA (0.42) | IDO1PPARAPPARGPPARDTAAR1 | |
| SCHEMBL5710979 | 0.78 | TAAR1 (0.52) | IDO1PPARATAAR1 | |
| SCHEMBL113325 | 0.77 | TAAR1 (0.48) | TRPA1MAOAPPARAPPARGPPARD | |
| SCHEMBL9718322 | 0.77 | TRPA1 (0.50) | TRPA1LMNAIDO1AGXTMAOA | |
| SCHEMBL5761123 | 0.76 | IDO1 (0.47) | IDO1AGXTMAOBPPARAPPARG | |
| SCHEMBL24328379 | 0.76 | PPARA (0.66) | PPARAPPARGPPARD | |
| SCHEMBL5077193 | 0.74 | SLC6A4 (0.42) | MAOAMAOB | |
| SCHEMBL2329756 | 0.74 | CYP1A2 (0.47) | MAOBTDP1 | |
| SCHEMBL5074299 | 0.74 | SLC6A4 (0.38) | MAOAMAOB | |
| SCHEMBL13636136 | 0.74 | FFAR1 (0.30) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| EP-1242411-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046181-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0403841-B1 | PROCESS FOR THE PRODUCTION OF ARYLACETALDEHYDE-DIALKYLACETALS | HÜLS AKTIENGESELLSCHAFT (DE) | 1993-08-04 | — | — | EP | disclosed |
| US-5202500-A | Hydroformylation of halomethyl aromatics in presence of metal carbonyl catalyst, acid acceptor, orthoester | HUELS AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |
| US-5068248-A | Analgesics, antipyretics and antiinflammatory agents | MERCK & CO., INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0160408-B1 | BENZOTHIOPHENES, THEIR PRODUCTION AND USE, AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4760086-A | N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0160408-A1 | Benzothiophenes, their production and use, and compositions containing them | MERCK & CO. INC. (US) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | TRPA1 1805/4885LMNA 3706/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.